FMP
Twist Bioscience Corporation
TWST
NASDAQ
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
50.66 USD
3.1 (6.12%)
InvestorPlace
Aug 7, 2024
Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen.
Parth Sanghvi
Aug 6, 2024
Twist Bioscience Reports Robust Q3 Growth and Targets Higher Margins: Key Insights from the Earnings Call Twist Bioscience has recently shared its Q3 earnings report, highlighting impressive growth and ambitious plans for increasing profit margins. The company’s earnings call provided valuable details on its performance, strategic goals, and future outlook. Here’s a comprehensive overview of Twist Bioscience’s recent achievements and strategic focus. Highlights from Twist Bioscience’s Q3 E...
InvestorPlace
Aug 5, 2024
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.
Seeking Alpha
Aug 4, 2024
Twist Bioscience reported revenue of $81.5 million in Q2 (fiscal Q3), marking a 28% increase from Q2, 2023. Twist's biopharma segment underperformed, contributing to a significant impairment charge. The company's future relies on its synthetic biology segment, facing competition and uncertain prospects in a rapidly evolving market.
Seeking Alpha
Aug 2, 2024
Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Patrick Finn - President and COO Conference Call Participants Steven Mah - Cowen Matt Larew - William Blair Luke Sergott - Barclays Vijay Kumar - Evercore ISI Sung-Ji Nam - Scotiabank Subbu Nambi - Guggenheim Securities Punee...
Zacks Investment Research
Aug 2, 2024
Twist Bioscience (TWST) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $1.01 per share a year ago.
Zacks Investment Research
Jul 30, 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Zacks Investment Research
Jul 26, 2024
Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research
Jul 22, 2024
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Zacks Investment Research
May 22, 2024
Does Twist Bioscience (TWST) have what it takes to be a top stock pick for momentum investors? Let's find out.